Skip to main content Back to Top
Advertisement

10/21/2026

Leucovorin Calcium Injection

Products Affected - Description

    • Leucovorin Calcium lyophilized powder for solution for injection, Fresenius Kabi, 500 mg, vial, 1 count, NDC 63323-0711-00
    • Leucovorin Calcium lyophilized powder for injection, Hikma, 100 mg, vial, 1 count, NDC 00143-9554-01
    • Leucovorin Calcium lyophilized powder for injection, Hikma, 50 mg, vial, 1 count, NDC 00143-9555-01
    • Leucovorin Calcium lyophilized powder for solution for injection, Hikma, 350 mg, vial, 1 count, NDC 00143-9552-01
    • Leucovorin Calcium lyophilized powder for solution for injection, Sagent, 50 mg, vial, 10 count, NDC 25021-0813-10
    • Leucovorin Calcium, Slate Run Pharmaceuticals, 200 mg, vial, 1 count, NDC 70436-0118-80
    • Leucovorin Calcium, Slate Run Pharmaceuticals, 350 mg, vial, 1 count, NDC 70436-0119-80

Reason for the Shortage

    • Fresenius Kabi did not provide a reason for the shortage.
    • Hikma did not provide a reason for the shortage.
    • Meitheal has leucovorin injection available.
    • Sagent has leucovorin on shortage due to increased demand.
    • Teva has discontinued leucovorin injection.
    • Viatris has leucovorin injection available.
    • Slate Run Pharmaceuticals did not provide a reason for the shortage. They are not actively marketing the 50 mg vials at this time.

Available Products

    • Leucovorin Calcium injection, Fresenius Kabi, 10 mg/mL, 10 mL vial, 1 count, NDC 63323-0631-10
    • Leucovorin Calcium injection, Fresenius Kabi, 10 mg/mL, 50 mL vial, 1 count, NDC 63323-0631-50
    • Leucovorin Calcium, Fresenius Kabi, 200 mg, vial, 1 count, NDC 63323-0710-50
    • Leucovorin Calcium lyophilized powder for injection, Hikma, 200 mg, vial, 1 count, NDC 00143-9553-01
    • Leucovorin Calcium, Meitheal Pharmaceuticals, 100 mg, vial, 1 count, NDC 71288-0161-20
    • Leucovorin Calcium, Meitheal Pharmaceuticals, 200 mg, vial, 1 count, NDC 71288-0162-30
    • Leucovorin Calcium, Meitheal Pharmaceuticals, 350 mg, vial, 1 count, NDC 71288-0163-30
    • Leucovorin Calcium, Meitheal Pharmaceuticals, 50 mg, vial, 1 count, NDC 71288-0160-10
    • Leucovorin Calcium, Meitheal Pharmaceuticals, 500 mg, vial, 1 count, NDC 71288-0164-50
    • Leucovorin Calcium lyophilized powder for injection, Mylan Institutional (Viatris), 200 mg, vial, 1 count, NDC 67457-0529-20
    • Leucovorin Calcium lyophilized powder for injection, Mylan Institutional (Viatris), 350 mg, vial, 1 count, NDC 67457-0530-35
    • Leucovorin Calcium lyophilized powder for injection, Mylan Institutional (Viatris), 50 mg, vial, 1 count, NDC 67457-0528-10
    • Leucovorin Calcium lyophilized powder for injection, Sagent, 100 mg, vial, 10 count, NDC 25021-0814-30
    • Leucovorin Calcium lyophilized powder for injection, Sagent, 200 mg, vial, 1 count, NDC 25021-0815-30
    • Leucovorin Calcium lyophilized powder for injection, Sagent, 350 mg, vial, 1 count, NDC 25021-0816-30
    • Leucovorin Calcium lyophilized powder for injection, Sagent, 500 mg, vial, 1 count, NDC 25021-0828-50
    • Leucovorin Calcium, Slate Run Pharmaceuticals, 100 mg, vial, 1 count, NDC 70436-0117-80
    • Leucovorin Calcium, Slate Run Pharmaceuticals, 500 mg, vial, 1 count, NDC 70436-0120-80

Estimated Resupply Dates

    • Fresenius Kabi has leucovorin 500 mg vials on back order and the company estimates a release date of late-October 2026.
    • Hikma has leucovorin 50 mg, 100 mg, and 350 mg vials on back order and the company estimates a release date of mid-December 2026 for the 50 mg vials and mid-November 2026 for the 100 mg and 350 mg vials.
    • Sagent has leucovorin 50 mg vials on back order and the company estimates a release date of October 2026.
    • Slate Run has leucovorin 200 mg and 350 mg vials on back order and the company estimates a release date of mid-November 2026.

Updated

Updated October 21, 2026 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 6, 2010 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2026, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.
ADVERTISEMENT